Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...

Following the disappointment of a multiple sclerosis (MS) trial readout this week, Sanofi has signed a pair of deals in the ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its ...

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Korean biopharmaceutical company Adel announced Monday that it has secured a license-out agreement worth up to $1.04 billion ...